P4 capped amides and lactams as HCV NS3 protease inhibitors with improved potency and DMPK profile
Latha G Nair1, Mousumi Sannigrahi, Stephane Bogen
1Chemical Research, Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. latha.nair@spcorp.com
Abstract:
SAR studies on the extension of P3 unit of Boceprevir (1, SCH 503034) with amides and lactams and their synthesis is described. Extensive SAR studies resulted in the identification of 36 bearing 4, 4-dimethyl lactam as the new P4 cap unit with improved potency (K(i)( *)=15nM, EC 90=70nM) and pharmacokinetic properties (Rat AUC (PO)=3.52microMh) compared to 1.
More Related Videos
Related Concept Videos
Antiviral Nucleoside Inhibitors
Dipeptidyl Peptidase 4 Inhibitors
Inhibitors of Virion Maturation and Assembly
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Antifungal Agents
Inhibitors of Viral Protein Synthesis


